{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:23:56Z","timestamp":1779110636981,"version":"3.51.4"},"reference-count":22,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,2,26]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Catastrophic antiphospholipid syndrome (CAPS) is a life-threatening form of antiphospholipid syndrome characterised by diffuse arterial and venous thrombosis, in the presence of positive antiphospholipid antibodies. The multiple sites of thrombosis in small, medium and large vessels progress to multiorgan failure, accounting for the high mortality rate associated with CAPS. Unregulated complement activation is increasingly recognised as critical to the pathogenesis of CAPS. Early diagnosis is essential to initiate prompt life-saving treatment with the triple therapy of anticoagulation, immunosuppression and either plasmapheresis or intravenous immunoglobulin. Among other immunosuppressive agents, eculizumab, a complement inhibitor has demonstrated efficacy in treatment-resistant cases.<\/jats:p>\n               <jats:p>We report an instructive case of a woman presenting with both clinical and laboratory findings consistent with primary CAPS, resistant to initial treatment and responsive to eculizumab, with emphasis on genetic testing and implications for future therapy.<\/jats:p>","DOI":"10.1136\/bcr-2022-254449","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T12:05:32Z","timestamp":1709640332000},"page":"e254449","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Eculizumab therapy and complement regulation in a case of resistant catastrophic antiphospholipid syndrome"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3670-2963","authenticated-orcid":false,"given":"Rachel","family":"Frederick","sequence":"first","affiliation":[{"name":"Department of Nephrology, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Victoria, Australia"},{"name":"Department of General Medicine, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Zolio","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evange","family":"Romas","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Victoria, Australia"},{"name":"The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Ierino","sequence":"additional","affiliation":[{"name":"Department of Nephrology, St Vincent's Hospital Melbourne Pty Ltd, Fitzroy, Victoria, Australia"},{"name":"The University of Melbourne, Melbourne, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"2025082801393500000_17.3.e254449.1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-019-00565-8"},{"key":"2025082801393500000_17.3.e254449.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213"},{"key":"2025082801393500000_17.3.e254449.3","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu394oa"},{"key":"2025082801393500000_17.3.e254449.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224609"},{"key":"2025082801393500000_17.3.e254449.5","first-page":"9","article-title":"Catastrophic antiphospholipid syndrome: a clinical review","volume":"3","author":"Nayer","year":"2014","journal-title":"J Nephropathol"},{"key":"2025082801393500000_17.3.e254449.6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.23736\/S0031-0808.17.03324-9","article-title":"Catastrophic antiphospholipid syndrome: an update","volume":"59","author":"Espinosa","year":"2017","journal-title":"Panminerva Med"},{"key":"2025082801393500000_17.3.e254449.7","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \"CAPS Registry\"","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2025082801393500000_17.3.e254449.8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"Chaturvedi","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2025082801393500000_17.3.e254449.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.10461"},{"key":"2025082801393500000_17.3.e254449.10","article-title":"36-year-old female with catastrophic Antiphospholipid syndrome treated with Eculizumab: a case report and review of literature","volume":"2014","author":"Strakhan","year":"2014","journal-title":"Case Rep Hematol"},{"key":"2025082801393500000_17.3.e254449.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003863"},{"key":"2025082801393500000_17.3.e254449.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103072","article-title":"Kidney disease in antiphospholipid antibody syndrome: risk factors, pathophysiology and management","volume":"21","author":"Scheen","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2025082801393500000_17.3.e254449.13","doi-asserted-by":"crossref","DOI":"10.3390\/medicina57090912","article-title":"Successful treatment of catastrophic antiphospholipid syndrome using rituximab: case report and review of the literature","volume":"57","author":"Stanescu","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"2025082801393500000_17.3.e254449.14","first-page":"346","article-title":"The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus","volume":"34","author":"Bayraktar","year":"2007","journal-title":"J Rheumatol"},{"key":"2025082801393500000_17.3.e254449.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312890"},{"key":"2025082801393500000_17.3.e254449.16","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.ajkd.2019.08.032","article-title":"mTORC pathway activation and effect of sirolimus on native kidney antiphospholipid syndrome nephropathy: a case report","volume":"76","author":"Dufour","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2025082801393500000_17.3.e254449.17","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/art.41891","article-title":"Expert perspective: management of microvascular and catastrophic antiphospholipid syndrome","volume":"73","author":"Erkan","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025082801393500000_17.3.e254449.18","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key228"},{"key":"2025082801393500000_17.3.e254449.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.37759"},{"key":"2025082801393500000_17.3.e254449.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.05.004"},{"key":"2025082801393500000_17.3.e254449.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0910965"},{"key":"2025082801393500000_17.3.e254449.22","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.12540"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-254449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:39:45Z","timestamp":1756370385000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-254449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,5]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/bcr-2022-254449"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-254449","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}